glp-1 side effects cancer Sharing some research on medications (weight loss/ anti obesity medications) and breast from the San Antonio Breast Cancer Symposium. We are beginning to see some early signals that they may GLP-1 drugs may reduce the

Follow-ups were scheduled approximately every 12 months, always confirming the same therapy for each treatment cycle

This is worth monitoring but rarely led to treatment discontinuation

Mounjaro is a dual action GLP-1 and GIP receptor agonist developed by Eli Lilly

Giuntini M, Baldacci F, Del Prete E, Bonuccelli U, Ceravolo R

Although many research groups have explored ways to enhance absorption, the gastrointestinal tract remains an environment that rapidly disrupts peptide structures through enzymatic cleavage, pH-induced denaturation, and limited permeability across epithelial barriers

reassess after several weeks using objective logs and patient-reported feedback